Diamyd Medical AB (OSTO:DMYD B) Margin of Safety % (DCF Dividends Based): N/A (As of Aug. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:DMYD B Diamyd Medical AB OSTO:DMYD B
41 GF Score
Price kr1.01
GF Value kr13.67
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Diamyd Medical AB Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Diamyd Medical AB's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

OSTO:DMYD B vs VRTX, REGN, RVMD: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Diamyd Medical AB's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diamyd Medical AB Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's Margin of Safety % (DCF Dividends Based) falls into.


OSTO:DMYD B
41GF Score
Diamyd Medical AB OSTO:DMYD B
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Diamyd Medical AB (OSTO:DMYD B) Overvalued in 2026?

Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be undervalued. The current stock price of kr1.01 is trading 92.6% below its estimated GF Value™ of kr13.67. GuruFocus considers Diamyd Medical AB to be Possible Value Trap.

Key valuation signals for OSTO:DMYD B:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: kr13.67 vs. price of kr1.01 (92.6% below fair value)
  • GF Score™: 41/100 with 3 warning signs

No single metric tells the full story. See the OSTO:DMYD B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diamyd Medical AB Business Description

Other Exchanges DMN:Germany
Address Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
41GF Score

Get the complete analysis for OSTO:DMYD B

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.01
Price
kr13.67
GF Value